FABP5 and type 2 diabetes mellitus: Since FABP4 and FABP5 act at the interface of metabolic and inflammatory pathways and play a significant role in the development of insulin resistance, type 2 diabetes, and atherosclerosis, it is expected that modification of the function of these FABPs may provide a new class of multi-indication therapeutic agents.